资讯

Citi Raises Kymera (KYMR) Price Target After Positive Drug Data, Keeps Buy Rating
Citi analysts increased the price target on Kymera Therapeutics, Inc. (NASDAQ:KYMR) from $52 to $60 and kept a “Buy” rating.